Gavin Cull

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 432 citations · Full text

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine S. Tam, Judith Trotman, Stephen Opat et al. · Blood · 2019 · 355 citations · Full text

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina et al. · The Lancet Oncology · 2019 · 229 citations

Neuro-oncology, Lymphoid Neoplasia, Medicine +9

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb et al. · Blood · 2020 · 105 citations · Full text

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Constantine S. Tam, Stephen Opat, David Simpson et al. · Blood Advances · 2021 · 96 citations · Full text